International Case Reports Journal (ISSN: 2770-9647) | Volume 1, Issue 1 | Short Communication | Open Access
Madhu Malleshappa1*, Ramanan Natarajan2 1Associate Professor, School of Sciences, Department of Life Sciences, Garden City University, India 2Research Scholar, School of Computational Sciences & IT, Department of Computer Science, Garden City University, India
*Correspondence to: Madhu MalleshappaFulltext PDF
Vaccines are the lifeblood of stopping any pandemic, and closely monitored vaccine trials are essential to collect correct data. Good data means safe and effective vaccine for the population. The trials need to be conducted on a sufficiently large population (post the initial safety test) with diverse gender (male, female, non-binary), demographic, ethnographic, socio-economic status, and other parameters to ensure that the vaccine is safe for all strata of people.
Citation:Madhu Malleshappa (2021) Sars-Cov-2 (Covid-19) Vaccine Trials – Perspective Int Case Rep Jour 1(1): 1-4.